

# SCHEDULE

September 2<sup>nd</sup>

From 19.00 **Welcome Reception**  
City Hall of Toulouse Mr Pierre Cohen, Mayor of Toulouse

September 3<sup>rd</sup>

8.30 **Registration Opening – 1st floor**  
Centre de congrès Pierre Baudis

8.30–9.30 Welcome Coffee

9.30–10.00

## WELCOME ADDRESS

Mr Pierre Montoriol, President of Cancer-Bio-Santé,  
Mr Jónas Einarsson, President of Oslo Cancer Cluster  
and Mr Jean-Claude Muller, Senior VP Prospective and  
Strategic Initiatives, sanofi-aventis.

**Moderator of the day:** Mr Jónas Einarsson, President  
of Oslo Cancer Cluster

10.00–11.00

## KEY NOTE PRESENTATIONS

How to evaluate the oncology industry  
as per today and for the coming  
3–5 years?

**Moderator:** Mr Jean-Jacques Garaud, Chief Medical  
Officer – Head of Global Drug Development, Roche

- **New therapeutic approaches – Cancer stem-cells  
research:** Prof. Stefan Krauss, Head of CAST Biomedical  
Innovation Center, Oslo University Hospital

- **Bioproduction:** Mr Edward Balbirnie, Director of  
Bioproduction, LFB

- **Questions & Answers**

B TO B MEETINGS  
INVESTMENT ROOM

11.00–11.20

Coffee Break

11.20–12.30

## ROUND TABLE

How to build partnerships  
with investors?

**Moderator:** Mr Mike Ward, Senior Editor, BioCentury

- **Introduction: How do investors evaluate the  
oncology market?**

- **How to attract capital to your business?**

Mrs Rafaèle Tordjman, Partner, Sofinnova Partners

Mrs Emma Palmer Foster, Emma Palmer Foster Consulting

Mr Matthieu Coutet, Investment Manager, Inserm

Mr Chandra Leo, HBM Partners

- **Questions & Answers**

B TO B MEETINGS  
INVESTMENT ROOM

12.30–14.00

Lunch

14.00– 14.20

## PHARMA NEEDS

How do sanofi-aventis build  
partnerships with oncology SMEs?

Dr Patrick Tricoli, MBA, Senior Director, R&D External  
Innovation Department, Access to Innovation Europe  
Head, sanofi-aventis

- **Questions & Answers**

14.20–15.15

## SME'S PRESENTATIONS

**Moderator:** Mr Jean-Pierre Bizzari, Senior Vice-President  
and Group Head of Global Oncology and Hematology, Celgene  
Cayla InvivoGen, Lytix Biopharma and Quidd introduce  
their latest achievements.

B TO B MEETINGS  
INVESTMENT ROOM

15.15–15.30

Coffee Break

15.30–16.40

## ROUND TABLE

IMI – Innovative Medicines Initiative  
“The IMI oncology call 2009”

**Moderator:** Mr Matthias Gottwald, R&D Liaison Officer,  
Bayer Schering Pharma

- **Introduction by Mr Daniel Vasmant**, Head of Health,  
Biotech & food Industry, General Directorate for  
Competitiveness, Industry and services

- **Academic panelist:** Prof. Carl Borrebäck – Director of  
Create Health – Lund University

- **Pharma panelist :** Dr Patrick Tricoli, MBA, Senior  
Director, R&D External Innovation Department, Access  
to Innovation Europe Head, sanofi-aventis

- **SMEs panelist:** Mr Erik Christensen – CEO – Diagenic

- **Questions & Answers**

B TO B MEETINGS  
INVESTMENT ROOM

16.40– 17.00

## PHARMA NEEDS

How do Pierre Fabre build partnerships  
with oncology SMEs?

Mr Laurent Nguyen, MD. - VP, Corporate Licensing &  
Acquisitions - Pierre Fabre

- **Questions & Answers**

From 19.00

## Networking Evening

Welcome address by Mr Jean-Jacques Romatet,  
General Director, CHU Toulouse

Speeches by Prof. Jean-Pierre Armand, General Direc-  
tor, Institut Claudius Regaud, Mr Tarald Brautaset,  
Ambassador of Norway, Mr Martin Malvy, Président  
of Conseil Régional Midi-Pyrénées, Mr Dominique Bur,  
Prefect of Region Midi-Pyrénées

# SCHEDULE

September 4<sup>th</sup>

8.30	Registration Opening		
8.30–9.30	Welcome Coffee	Speeches by <b>Mr Pierre Cohen</b> , Mayor of Toulouse - President of Toulouse Cancer Campus and <b>Mr Alain di Crescenzo</b> , President of the Industry and Services Commission, Chamber of Commerce and Industry of Toulouse - President of Destination International	
9.30–10.30	<b>ROUND TABLE</b> Establishment of a phase I Clinical Studies Network in Europe?	<b>Moderator:</b> Prof. Sigbjorn Smeland, Head of Cancer Clinic, Oslo University Hospital <b>Panelists:</b> <b>Mr Jean-Pierre Armand</b> , General Director, Institut Claudius Regaud, Toulouse <b>Prof. Steinar Aamdal</b> , The Norwegian Radium Hospital, Oslo <b>Prof. Manuel Hidalgo</b> , Director of the Clinical Research Program, CNIO, Madrid <b>Prof. Gerd Mikus</b> , Deputy Medical Director of the Department's Clinical Research Unit, UniversitätsKlinikum – Heidelberg <b>Dr. Udai Banerji</b> , Senior Lecturer and Honorary Consultant, Royal Marsden Hospital, London • <b>Questions &amp; Answers</b>	<b>B TO B MEETINGS</b> <b>INVESTMENT ROOM</b>
10.30– 10.50	<b>PHARMA NEEDS</b> How do MSD build partnerships with oncology SMEs?	<b>Mr Hans Boström</b> , Director of Licensing and External Research - MSD	
10.50–11.00	Coffee Break		
11.00–12.00	<b>ROUND TABLE</b> Expectations from pharmas towards biotech community	<b>Moderator:</b> Benedikt Timmerman, CEO, BT Pharma <b>Panelists:</b> <b>Mr Campbell Wilson</b> , Director, Strategic Planning and Business Development, AstraZeneca <b>Mr Luc Aguilar</b> , External R&D Director, Pierre Fabre <b>Mr Pierre Casellas</b> , Scientific Director, External Innovation Department, sanofi-aventis. <b>Mr Hans Boström</b> , Director of Licensing and External Research, MSD <b>Mr Dieter Zopf</b> , GDD TRG Oncology External Innovations, Bayer Schering Pharma <b>Dr. Oliver Kisker</b> , Senior Vice President – Head of Global Clinical Development Unit – Oncology, Merck Serono • <b>Questions &amp; Answers</b>	<b>B TO B MEETINGS</b> <b>INVESTMENT ROOM</b>
12.00–13.00	Lunch		
13.00–14.00	<b>KEY NOTE PRESENTATIONS</b> Imaging Biomarkers	<b>Moderator:</b> Prof. Alain Roche, Chairman of the Department of Medical imaging, Institut Gustave Roussy, Paris <b>Panelists:</b> <b>Prof. Hervé Rousseau</b> , Radiology Service, Centre Hospitalier Universitaire, Toulouse <b>Dr. Frédéric Courbon</b> , Department of Medical Imaging, Institut Claudius Regaud, Toulouse <b>Mr Bertrand Loubaton</b> , Pharmaceutical and Academic Collaborations Manager, GE Healthcare <b>Mr Rudi Verbruggen</b> , Siemens • <b>Questions &amp; Answers</b>	<b>B TO B MEETINGS</b> <b>INVESTMENT ROOM</b>
14.00–15.00	<b>SMEs PRESENTATIONS</b>	<b>Moderator:</b> Mr Bernhard Ehmer, Senior VP and Managing Director, International Operations, ImClone Systems International Almac Discovery, Biotec Pharmacon ASA, Genclis and PCI Biotech introduce their latest achievements.	
15.00–15.30	<b>CONCLUSION AND NEXT STEPS</b>	<b>Mr Jean-Pierre Saintouil</b> , CEO of Cancer-Bio-Santé <b>Mr Bjarte Reve</b> , CEO of Oslo Cancer Cluster	
From 15.30	Closing Cocktail		

Programme as of 31 August 2009.